



MAIL STOP: AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

In re application of: Ronald M. BURCH, et al.

Serial No.: 10/056,348

Filed: January 25, 2002

For: **ANALGESIC COMBINATION OF OXYCODONE AND NABUMETONE**

Sir:

Transmitted herewith is an **Information Disclosure Statement (2 pages)** in the above-identified application.

- ☐ Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.  
☐ Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.  
☒ No fee for additional claims is required.  
☐ A filing fee for additional claims calculated as shown below, is required:

- ☒ Also transmitted herewith are:  
☐ Petition for extension under 37 C.F.R. 1.136  
☒ Other: **Form PTO-1449 (2 pages) with copies of cited references, and return receipt postcard.**

- ☐ Check(s) in the amount of \$ **0.00** is attached to cover:  
☐ Filing fee for additional claims under 37 C.F.R. 1.16  
☐ Petition fee for extension under 37 C.F.R. 1.136  
☐ Other:

- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.
- ☐ Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.  
☒ Any patent application processing fees under 37 C.F.R. 1.17.  
☐ Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.

  
Oleg Ioselevich, Reg. No. 56,963  
DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
Tel: (212) 736-1940  
Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Mail Stop: Amendment Commissioner for Patents, Alexandria, VA 22313-1450" on November 15, 2007.  
DAVIDSON, DAVIDSON & KAPPEL, LLC

BY: 

Luis Baez



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No. : 10/056,348  
 Applicant : Ronald M. BURCH, et al.  
 Filed : January 25, 2002  
 Art Unit : 1639  
 Examiner : Sue Xu LIU  
 For : **ANALGESIC COMBINATION OF  
 OXYCODONE AND NABUMETONE**  
 Attorney Docket No.: 200.1079CON4  
 Customer No. : 23280

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

November 15, 2007

**INFORMATION DISCLOSURE  
 STATEMENT UNDER 37 C.F.R. § 1.56**

Sir:


In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record documents listed on the accompanying Form PTO-1449 (2 pages) for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with 37 C.F.R. 1.98(a)(2), a copy of each document cited on accompanying Form PTO-1449 (2 pages) is enclosed. If it is determined that a copy of any of the cited documents is missing and is required, the Examiner is respectfully requested to contact the undersigned so that the missing copy may be forwarded.

It is respectfully requested that the documents cited on the accompanying Form PTO-1449 (2 pages) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b)(4), “[b]efore the mailing of a first Office action after the filing of a request for continued examination under § 1.114.” Accordingly, no fee is believed due. If it is determined that a fee is due in connection with the filing of this Information Disclosure Statement, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By:   
Oleg Ioselevich  
Reg. No. 56,963

DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14th Floor  
New York, New York 10018  
(212) 736-1940